| Previous Close | 0.12 |
| Open | 0.11 |
| Bid | 0.11 x |
| Ask | 0.12 x |
| Day's Range | 0.11 - 0.11 |
| 52 Week Range | 0.04 - 0.19 |
| Volume | 3,000 |
| Avg. Volume | 48,885 |
| Market Cap | 16.89M |
| Beta | 3.38 |
| PE Ratio (TTM) | -3.24 |
| EPS (TTM) | -0.03 |
| Earnings Date | N/A |
| Dividend & Yield | 0.00 (0.00%) |
| Ex-Dividend Date | 2005-07-21 |
| 1y Target Est | N/A |
- CNW Group•5 days ago
Quest PharmaTech Appoints Mr. Mark Lievonen, former President of Sanofi Pasteur Limited, to the Board of Directors
Quest PharmaTech Appoints Mr. Mark Lievonen, former President of Sanofi Pasteur Limited, to the Board of Directors
- CNW Group•27 days ago
OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer
OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer
- PR Newswire•27 days ago
OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer
EDMONTON, June 27, 2017 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a privately held, cancer immunotherapy company, today announced the appointment of Hany Awadalla, as its Senior Vice President and Chief Financial Officer. Mr. Awadalla has spent almost 30 years in healthcare investment banking at Merrill Lynch, UBS, and serving as Head of Healthcare M&A at Robertson Stephens and Wells Fargo and Head of Healthcare Investment Banking at Unterberg Towbin. Most recently and for the past 6 years, he served as Managing Director at National Securities.
